What are Humira's long-term serious side effects across adult indications, including RA? “SAEs of interest across 8 adult indications2,†
Rates displayed as events per 100 PYs
Rheumatoid arthritis
(RA)
37,106 PYs
N=15,512 Ankylosing spondylitis
(AS)
2,120 PYs
N=2,026 Psoriatic arthritis
(PsA)
998 PYs
N=837 Plaque psoriasis
(Ps)
5,479 PYs
N=3,732 Hidradenitis suppurativa
(HS)
1,198 PYs
N=733 Crohn’s disease
(CD)
4,359 PYs
N=3,896 Ulcerative colitis
(UC)
3,407 PYs
N=1,739 Uveitis
(UV)a
1,151 PYs
N=464
Serious infection 3.9 1.8 2.8 1.8 2.8 6.9 3.5 4.1
Tuberculosis 0.2 0.1 0.2 0.2 0 0.2 <0.1 0.4
Active 0.2 0.1 0.2 0.2 0 0.1 <0.1 0.2
Latent <0.1 0 0 0 0 <0.1 0 0.3
Opportunistic infectionb <0.1 0 0 0 0 <0.1 <0.1 0.4
Demyelinating disorder <0.1 <0.1 0 0 0 0.1 <0.1 0.3
Lupus-like syndrome <0.1 <0.1 0 0 0 <0.1 <0.1 <0.1
Congestive heart failure 0.2 <0.1 0 0.1 0.2 0 <0.1 <0.1
Ps new onset/worsening <0.1 <0.1 0.1 <0.1 <0.1 <0.1 <0.1 0
Malignancyc 0.7 0.2 0.2 0.5 0.5 0.4 0.6 0.7
Lymphoma 0.1 <0.1 0.2 <0.1 <0.1 <0.1 <0.1 <0.1
NMSC 0.2 0.2 0.1 0.1 <0.1 <0.1 <0.1 0.2
Melanoma <0.1 <0.1 0 0.2 0 0 <0.1 0
Sarcoidosis <0.1 <0.1 0 0 0 0 0 <0.1
Any AE leading to death 0.6 <0.1 0.3 0.2 0.5 0.1 0.1 0.6” (opens the source at this quote in a new tab) Copy Flag
“a Non-infectious (NI) intermediate, posterior, and panuveitis.
b Excludes oral candidiasis and tuberculosis.
c Excludes lymphoma, hepatosplenic T-cell lymphoma, leukemia, NMSC, and melanoma.
*33 in RA, 5 in AS, 3 in PsA, 13 in Ps, 3 in HS, 11 in CD, 4 in UC, and 2 in Non-infectious (NI) intermediate, posterior, or panuveitis.
† Data derived from global clinical trials of HUMIRA, including randomized controlled, open-label, and long-term extension studies (33 in RA, 5 in AS, 3 in PsA, 13 in Ps, 3 in HS, 11 in CD, 4 in UC, and 2 in UV).2 ” (opens the source at this quote in a new tab) Copy Flag
Note: The first value column of the table is rheumatoid arthritis (37,106 patient-years, N=15,512); rates are events per 100 patient-years. The page cites Burmester GR, et al. Adv Ther. 2020;37(1):364-380.